Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Report 2026

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview

• Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer market size has reached to $1.31 billion in 2025 • Expected to grow to $1.64 billion in 2030 at a compound annual growth rate (CAGR) of 4.6% • Growth Driver: Rising Adoption Of Targeted Cancer Therapy Fueling The Growth Of The Market Due To Advancements In Genetic Profiling • Market Trend: FDA Approval Advances Immunotherapy For Gastric Cancer • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer is a subtype of gastric (stomach) or gastroesophageal junction cancer in which the cancer cells have higher than normal levels of the human epidermal growth factor receptor 2 (HER2) protein or gene amplification, which promotes cancer cell growth. This subtype can be targeted with specific therapies, improving treatment outcomes in eligible patients. The main therapy types for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer are chemotherapy, immunotherapy, radiation therapy, and targeted therapy. Chemotherapy uses powerful drugs that travel through the bloodstream to destroy fast-growing cancer cells, including those in HER2-positive gastric cancer. It is used for various stages, which include stage I, stage II, stage III, and stage IV, for varied end users such as ambulatory surgery centers, hospitals and specialty clinics, and others.

What Is The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Growth Forecast?

The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market size is expected to see steady growth in the next few years. It will grow to $1.64 billion in 2030 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to development of novel antibody-drug conjugates, increasing clinical trials for her2-targeted therapies, rising healthcare infrastructure in emerging markets, growth in precision medicine and biomarker testing, expanding ambulatory surgery centers and specialty oncology clinics. Major trends in the forecast period include increasing adoption of her2-targeted therapies, rising awareness of gastric cancer subtypes, expansion of immunotherapy and monoclonal antibody usage, growth in personalized treatment approaches, enhanced focus on early detection and diagnostic testing.

Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Segmentation

1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy 2) By Stage: Stage I, Stage II, Stage III, Stage IV 3) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users Subsegments: 1) By Chemotherapy: Fluoropyrimidines, Platinum-Based Agents, Taxanes, Irinotecan, Anthracyclines 2) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cancer Vaccines, Cytokine-Based Therapies 3) By Radiation Therapy: External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, 3D Conformal Radiation Therapy 4) By Targeted Therapy: HER2-Targeted Therapies, Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, mTOR Inhibitors, PI3K/AKT/mTOR Pathway Inhibitors

What Is The Driver Of The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

The rising adoption of targeted cancer therapy is expected to propel the growth in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market going forward. Targeted therapy, also known as personalized medicine, is a treatment approach that uses specific drugs or substances to block the growth of cancer by focusing on particular molecules involved in tumor development. The rise in targeted therapy use is largely due to advancements in genetic profiling, which allow for more precise treatments based on an individual's unique tumor characteristics, leading to improved effectiveness and fewer side effects. In HER2-positive gastric cancer, targeted therapy is used by directly attacking the HER2 protein, which is overexpressed in these tumors, slowing disease progression and enhancing patient outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based professional membership organization, the Food and Drug Administration (FDA) approved 16 new personalized medicines, including 7 drugs for cancer and 3 for various other diseases and conditions in 2023, indicating an increase from 6 in 2022. Therefore, the rising adoption of targeted cancer therapy is driving the growth of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer industry.

Key Players In The Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

Major companies operating in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.

Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Trends and Insights

Major companies operating in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market are focusing on gaining approvals for innovative therapies such as advanced immunotherapy-enhanced combination regimens, such as the integration of immune checkpoint inhibitors with targeted therapy and chemotherapy, to significantly improve patient outcomes in first-line treatment settings. The advanced immunotherapy-enhanced combination regimens approach leverages the body's immune system by inhibiting programmed death (PD)-1 or programmed death (PD)-L1 interaction while simultaneously targeting HER2 receptors and using chemotherapeutic agents, thereby amplifying anti-tumor activity and enhancing survival rates. For instance, in March 2025, Merck & Co., Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for pembrolizumab (Keytruda), in combination with trastuzumab and chemotherapy, as a first-line treatment for adults with HER2-positive unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express programmed death (PD)-L1. This newly approved combination therapy demonstrated a substantial improvement in median progression-free survival and overall survival compared to standard regimens. With a higher overall response rate of 73% and a longer median duration of response, the treatment represents a paradigm shift in managing advanced HER2-positive gastric cancers.

What Are Latest Mergers And Acquisitions In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

In December 2023, Pfizer Inc., a US-based pharmaceutical industry company, acquired Seagen Inc. for an undisclosed amount. Through this acquisition, Pfizer Inc. aims to strengthen its oncology portfolio, enhance its capabilities in targeted cancer therapies. Seagen Inc. is a US-based biotechnology company that specializes in HER2-positive gastric cancer treatments.

Regional Insights

North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market consists of sales of trastuzumab, pertuzumab, margetuximab, and lapatinib. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Report 2026?

The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.